These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 26081429)

  • 1. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo.
    Joel M; Mughal AA; Grieg Z; Murrell W; Palmero S; Mikkelsen B; Fjerdingstad HB; Sandberg CJ; Behnan J; Glover JC; Langmoen IA; Stangeland B
    Mol Cancer; 2015 Jun; 14():121. PubMed ID: 26081429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
    Kim DJ; Li Y; Reddy K; Lee MH; Kim MO; Cho YY; Lee SY; Kim JE; Bode AM; Dong Z
    Cancer Res; 2012 Jun; 72(12):3060-8. PubMed ID: 22523035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
    Ishikawa C; Senba M; Mori N
    Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
    Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
    Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC.
    Kar A; Zhang Y; Yacob BW; Saeed J; Tompkins KD; Bagby SM; Pitts TM; Somerset H; Leong S; Wierman ME; Kiseljak-Vassiliades K
    Endocr Relat Cancer; 2019 Oct; 26(10):765-778. PubMed ID: 31325906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo.
    Lamour V; Henry A; Kroonen J; Nokin MJ; von Marschall Z; Fisher LW; Chau TL; Chariot A; Sanson M; Delattre JY; Turtoi A; Peulen O; Rogister B; Castronovo V; Bellahcène A
    Int J Cancer; 2015 Sep; 137(5):1047-57. PubMed ID: 25620078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survival.
    Wang MY; Lin ZR; Cao Y; Zheng LS; Peng LX; Sun R; Meng DF; Xie P; Yang JP; Cao L; Xu L; Huang BJ; Qian CN
    Oncotarget; 2016 May; 7(18):26604-16. PubMed ID: 27049917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
    Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
    J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis.
    Liu Y; Liu H; Cao H; Song B; Zhang W; Zhang W
    Oncol Rep; 2015 Dec; 34(6):3288-96. PubMed ID: 26503118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase.
    Wang L; Zhang Z; Ge R; Zhang J; Liu W; Mou K; Lv S; Mu X
    Anticancer Agents Med Chem; 2019; 19(8):1029-1036. PubMed ID: 30827262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
    Hu F; Gartenhaus RB; Eichberg D; Liu Z; Fang HB; Rapoport AP
    Oncogene; 2010 Oct; 29(40):5464-74. PubMed ID: 20622899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
    Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
    Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells.
    Mughal AA; Grieg Z; Skjellegrind H; Fayzullin A; Lamkhannat M; Joel M; Ahmed MS; Murrell W; Vik-Mo EO; Langmoen IA; Stangeland B
    Mol Cancer; 2015 Aug; 14():160. PubMed ID: 26292663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paired related homeobox 1 transactivates dopamine D2 receptor to maintain propagation and tumorigenicity of glioma-initiating cells.
    Li Y; Wang W; Wang F; Wu Q; Li W; Zhong X; Tian K; Zeng T; Gao L; Liu Y; Li S; Jiang X; Du G; Zhou Y
    J Mol Cell Biol; 2017 Aug; 9(4):302-314. PubMed ID: 28486630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PBK/TOPK expression correlates with mutant p53 and affects patients' prognosis and cell proliferation and viability in lung adenocarcinoma.
    Lei B; Qi W; Zhao Y; Li Y; Liu S; Xu X; Zhi C; Wan L; Shen H
    Hum Pathol; 2015 Feb; 46(2):217-24. PubMed ID: 25466965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
    Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
    Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suberoylanilide hydroxamic acid represses glioma stem-like cells.
    Hsu CC; Chang WC; Hsu TI; Liu JJ; Yeh SH; Wang JY; Liou JP; Ko CY; Chang KY; Chuang JY
    J Biomed Sci; 2016 Nov; 23(1):81. PubMed ID: 27863490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of the NFκB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo.
    Nogueira L; Ruiz-Ontañon P; Vazquez-Barquero A; Lafarga M; Berciano MT; Aldaz B; Grande L; Casafont I; Segura V; Robles EF; Suarez D; Garcia LF; Martinez-Climent JA; Fernandez-Luna JL
    Oncogene; 2011 Aug; 30(32):3537-48. PubMed ID: 21423202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
    Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
    Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.